XENON PHARMACEUTICALS INC. Revenue
XENON PHARMACEUTICALS INC. (XENE) reported Revenue of $16.00 thousand for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2018-03-07
- XENON PHARMACEUTICALS INC. revenues for the quarter ending 2017-12-31 was $16.00K, a 95.74% decline year-over-year.
- XENON PHARMACEUTICALS INC. revenues for the quarter ending 2017-09-30 was $264.00K, a 36.08% decline year-over-year.
- XENON PHARMACEUTICALS INC. revenues for the quarter ending 2017-06-30 was $15.00K, a 96.37% decline year-over-year.
- XENON PHARMACEUTICALS INC. revenues for the quarter ending 2017-03-31 was $16.00K, a 97.34% decline year-over-year.
- XENON PHARMACEUTICALS INC. revenues for fiscal 2017 was $311.00K, a 82.75% decline from fiscal 2016.
- XENON PHARMACEUTICALS INC. revenues for fiscal 2016 was $1.80M, a 88.43% decline from fiscal 2015.
- XENON PHARMACEUTICALS INC. revenues for fiscal 2015 was $15.58M, a 45.09% decline from fiscal 2014.
- XENON PHARMACEUTICALS INC. revenues for fiscal 2014 was $28.37M, a 3.71% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2017-12-31 | $16.00K 10-K · filed 2018-03-07 | $280.00K derived: sum of 2 quarters · filed 2018-03-07 | $295.00K derived: sum of 3 quarters · filed 2018-03-07 | $311.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | $264.00K 10-K · filed 2018-03-07 | $279.00K derived: sum of 2 quarters · filed 2018-03-07 | $295.00K 10-Q · filed 2017-11-07 | $671.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $15.00K 10-K · filed 2018-03-07 | $31.00K 10-Q · filed 2017-08-03 | $407.00K derived: sum of 3 quarters · filed 2018-03-07 | $820.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $16.00K 10-K · filed 2018-03-07 | $392.00K derived: sum of 2 quarters · filed 2018-03-07 | $805.00K derived: sum of 3 quarters · filed 2018-03-07 | $1.22M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | $376.00K 10-K · filed 2018-03-07 | $789.00K derived: sum of 2 quarters · filed 2018-03-07 | $1.20M derived: sum of 3 quarters · filed 2018-03-07 | $1.80M 10-K · filed 2018-03-07 |
| 2016-09-30 | $413.00K 10-K · filed 2018-03-07 | $826.00K derived: sum of 2 quarters · filed 2018-03-07 | $1.43M 10-Q · filed 2017-11-07 | $4.65M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $413.00K 10-K · filed 2018-03-07 | $1.01M 10-Q · filed 2017-08-03 | $4.24M derived: sum of 3 quarters · filed 2018-03-07 | $8.54M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $601.00K 10-K · filed 2018-03-07 | $3.83M derived: sum of 2 quarters · filed 2018-03-07 | $8.12M derived: sum of 3 quarters · filed 2018-03-07 | $12.17M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $3.23M 10-K · filed 2017-03-08 | $7.52M derived: sum of 2 quarters · filed 2017-03-08 | $11.57M derived: sum of 3 quarters · filed 2017-03-08 | $15.58M 10-K · filed 2018-03-07 |
| 2015-09-30 | $4.29M 10-K · filed 2017-03-08 | $8.34M derived: sum of 2 quarters · filed 2017-03-08 | $12.35M 10-Q · filed 2016-11-03 | $17.23M derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-06-30 | $4.05M 10-K · filed 2017-03-08 | $8.06M 10-Q · filed 2016-08-03 | $12.93M derived: sum of 3 quarters · filed 2017-03-08 | $26.13M derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-03-31 | $4.01M 10-K · filed 2017-03-08 | $8.89M derived: sum of 2 quarters · filed 2017-03-08 | $22.08M derived: sum of 3 quarters · filed 2017-03-08 | $27.38M derived: sum of 4 quarters · filed 2017-03-08 |
| 2014-12-31 | $4.88M 10-K · filed 2016-03-08 | $18.07M derived: sum of 2 quarters · filed 2016-03-08 | $23.37M derived: sum of 3 quarters · filed 2016-03-08 | $28.37M 10-K · filed 2017-03-08 |
| 2014-09-30 | $13.19M 10-K · filed 2016-03-08 | $18.49M derived: sum of 2 quarters · filed 2016-03-08 | $23.49M 10-Q · filed 2015-11-10 | $29.07M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | $5.30M 10-K · filed 2016-03-08 | $10.30M 10-Q · filed 2015-08-13 | $15.88M derived: sum of 3 quarters · filed 2016-03-08 | $26.67M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-03-31 | $5.00M 10-K · filed 2016-03-08 | $10.58M derived: sum of 2 quarters · filed 2016-03-08 | $21.37M derived: sum of 3 quarters · filed 2016-03-08 | $26.97M derived: sum of 4 quarters · filed 2016-03-08 |
| 2013-12-31 | $5.58M 10-K · filed 2015-03-12 | $16.37M derived: sum of 2 quarters · filed 2015-03-12 | $21.97M derived: sum of 3 quarters · filed 2015-03-12 | $27.36M 10-K · filed 2016-03-08 |
| 2013-09-30 | $10.79M 10-K · filed 2015-03-12 | $16.39M derived: sum of 2 quarters · filed 2015-03-12 | $21.77M 10-Q · filed 2014-12-15 | |
| 2013-06-30 | $5.60M 10-K · filed 2015-03-12 | $10.98M derived: sum of 2 quarters · filed 2015-03-12 | ||
| 2013-03-31 | $5.38M 10-K · filed 2015-03-12 | |||
| 2012-12-31 | $14.31M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |